These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24567265)

  • 1. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.
    Cho DC
    BioDrugs; 2014 Aug; 28(4):373-81. PubMed ID: 24567265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
    Mabuchi S; Kuroda H; Takahashi R; Sasano T
    Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K and cancer: lessons, challenges and opportunities.
    Fruman DA; Rommel C
    Nat Rev Drug Discov; 2014 Feb; 13(2):140-56. PubMed ID: 24481312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
    Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
    Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PI3K-AKT-mTOR signaling network in cancer.
    Khan KH; Yap TA; Yan L; Cunningham D
    Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.
    Manfredi GI; Dicitore A; Gaudenzi G; Caraglia M; Persani L; Vitale G
    Endocrine; 2015 Mar; 48(2):363-70. PubMed ID: 25115638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
    Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
    LoRusso PM
    J Clin Oncol; 2016 Nov; 34(31):3803-3815. PubMed ID: 27621407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
    Blachly JS; Baiocchi RA
    Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
    Markman B; Dienstmann R; Tabernero J
    Oncotarget; 2010 Nov; 1(7):530-543. PubMed ID: 21317449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the phosphoinositide 3-kinase pathway in cancer.
    Liu P; Cheng H; Roberts TM; Zhao JJ
    Nat Rev Drug Discov; 2009 Aug; 8(8):627-44. PubMed ID: 19644473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.